Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 7/20 | 0.45 |
| ▸ | SCN10A | Q9Y5Y9 | 7/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24518268 | 0.90 | MAPT (0.48) | SCN8ASCN10AMAPTNPSR1CYP1A2 | |
| SCHEMBL26369466 | 0.85 | DHODH (0.46) | SCN8ASCN10AMAPTNPSR1CYP1A2 | |
| SCHEMBL26233335 | 0.84 | SCN8A (0.61) | SCN8ASCN10A | |
| SCHEMBL28921178 | 0.80 | GAA (0.49) | SCN8ASCN10A | |
| SCHEMBL4300383 | 0.78 | SMN1; SMN2 (0.52) | MAPTNPSR1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL30974608 | 0.78 | ALDH1A1 (0.46) | SCN8ASCN10AMAPTNPSR1CYP1A2 | |
| SCHEMBL29250429 | 0.78 | ALDH1A1 (0.46) | SCN8ASCN10AMAPTNPSR1CYP1A2 | |
| SCHEMBL1505444 | 0.78 | HSP90AA1 (0.57) | MAPTNPSR1CYP3A4L3MBTL1HSP90AA1 | |
| SCHEMBL24518270 | 0.78 | SCN10A (0.61) | SCN8ASCN10A | |
| SCHEMBL24004462 | 0.77 | SCN8A (0.46) | SCN8ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303497-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USES THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD (CN) | 2023-09-28 | — | — | US | disclosed |
| WO-2022121517-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USE THEREOF | 成都海博为药业有限公司 | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303497-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USES THEREOF | SCN8A, SCN9A, SCN10A | SCN8A 1/4885SCN10A 3/4885MAPT 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.